Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveitis Uveitis is an inflammatory condition in which the patient's own immune system attacks the eye, causing eye inflammation and vision loss. Patients with uveitis may be treated with immunosuppressive medications to reduce the inflammation and prevent vision loss. - Sirolimus is an immunosuppressive medication that is approved by the U.S. Food and Drug Administration (FDA) to prevent organ rejection following a kidney transplant. Researchers think that sirolimus may affect the part of the immune system that may be an important cause of uveitis, and may decrease the inflammation that causes uveitis. - In this study, sirolimus will be given as an injection under the outer layer of your eye. The FDA has permitted the investigational use of sirolimus for this study.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research and Development Contracts (N01)
Project #
N01EY70001-12-0-29
Application #
7976132
Study Section
Project Start
2006-11-01
Project End
2011-10-31
Budget Start
Budget End
Support Year
Fiscal Year
2009
Total Cost
$68,934
Indirect Cost
Name
Emmes Corporation
Department
Type
DUNS #
096360284
City
Rockville
State
MD
Country
United States
Zip Code
20850